The global Small Nucleic Acid Drug market size is predicted to grow from US$ 6756 million in 2025 to US$ 19630 million in 2031; it is expected to grow at a CAGR of 19.5% from 2025 to 2031.
Small nucleic acid drugs, such as siRNA, ASO, miRNA, Aptamer, etc., function based on the RNAi process and offer various advantages, including unlimited target drug ability, high specificity, long half-life, faster and more efficient design, development and production process.
Small nucleic acid drugs, composed of nucleotides, represent a novel class of pharmaceuticals that differ significantly from conventional small molecule and antibody-based therapeutics. These agents function by selectively targeting specific genes or their corresponding messenger RNAs (mRNAs), further modulating gene expression and regulating translation-related processes. Prominent examples within this category include antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), microRNAs (miRNAs), and aptamers.
The Small Nucleic Acid Drug Market is driven by the transformative potential of small nucleic acids, including microRNA, aptamers, and small interfering RNA (siRNA), in treating a wide spectrum of diseases, from genetic disorders to cancer and viral infections. These therapies harness the power of small nucleic acids to modulate gene expression, inhibit specific targets, and diagnose diseases, offering a precise and personalized approach to treatment. As genomics and RNA-based research advance, and precision medicine gains prominence, the demand for small nucleic acid drugs continues to surge. Innovations in nucleic acid design, delivery systems, and gene-editing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to overcome hurdles related to safe and efficient drug delivery, minimize off-target effects, ensure long-term safety and efficacy, and navigate complex regulatory pathways. Addressing delivery challenges, optimizing pharmacokinetics, and managing development costs are ongoing hurdles. Additionally, the market faces competition from traditional therapeutic approaches, necessitating continuous research and development efforts to unlock the full therapeutic potential of small nucleic acid drugs. Striking a balance between providing safe, effective, and accessible small nucleic acid therapies while addressing scientific and regulatory challenges is paramount for the continued growth of the Small Nucleic Acid Drug Market.
North America is the largest consumption place, with a consumption market share nearly 55.11% in 2023. Following North Americas, Europe is the second largest consumption place with the consumption market share of 34.29%.
The global key companies of Small Nucleic Acid Drug include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, Jazz Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 94.96% in terms of revenue.
A key trend in the small nucleic acid drugs market is the development of advanced delivery systems to improve the stability and cellular uptake of these therapies. Lipid nanoparticles (LNPs), polymer-based carriers, and exosome-based delivery platforms are gaining traction due to their ability to protect nucleic acids from degradation and enhance target specificity. These innovations are crucial for overcoming the delivery challenges associated with small nucleic acid drugs, particularly for therapies targeting difficult-to-reach tissues such as the brain or tumors.
While small nucleic acid drugs initially focused on rare genetic disorders, there is a growing trend toward applying these therapies to more common diseases, such as cardiovascular conditions, autoimmune disorders, and metabolic diseases. This shift is driven by advancements in gene-editing tools and RNA interference technology, which expand the potential therapeutic targets. The broadening scope of indications is expected to significantly increase the market size and attract more pharmaceutical companies into this space.
The 鈥淪mall Nucleic Acid Drug Industry Forecast鈥� looks at past sales and reviews total world Small Nucleic Acid Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Small Nucleic Acid Drug sales for 2025 through 2031. With Small Nucleic Acid Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Nucleic Acid Drug industry.
This Insight Report provides a comprehensive analysis of the global Small Nucleic Acid Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Small Nucleic Acid Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Small Nucleic Acid Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Nucleic Acid Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Nucleic Acid Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Small Nucleic Acid Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
Other
Segmentation by Application:
Neuromuscular Diseases
hATTR
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
Jazz Pharmaceuticals
AstraZeneca
Novo Nordisk
Astellas Pharma
Geron Corporation
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Small Nucleic Acid Drug Market Size (2020-2031)
2.1.2 Small Nucleic Acid Drug Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Small Nucleic Acid Drug by Country/Region (2020, 2024 & 2031)
2.2 Small Nucleic Acid Drug Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 Other
2.3 Small Nucleic Acid Drug Market Size by Type
2.3.1 Small Nucleic Acid Drug Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Small Nucleic Acid Drug Market Size Market Share by Type (2020-2025)
2.4 Small Nucleic Acid Drug Segment by Application
2.4.1 Neuromuscular Diseases
2.4.2 hATTR
2.4.3 Other
2.5 Small Nucleic Acid Drug Market Size by Application
2.5.1 Small Nucleic Acid Drug Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Small Nucleic Acid Drug Market Size Market Share by Application (2020-2025)
3 Small Nucleic Acid Drug Market Size by Player
3.1 Small Nucleic Acid Drug Market Size Market Share by Player
3.1.1 Global Small Nucleic Acid Drug Revenue by Player (2020-2025)
3.1.2 Global Small Nucleic Acid Drug Revenue Market Share by Player (2020-2025)
3.2 Global Small Nucleic Acid Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Small Nucleic Acid Drug by Region
4.1 Small Nucleic Acid Drug Market Size by Region (2020-2025)
4.2 Global Small Nucleic Acid Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Small Nucleic Acid Drug Market Size Growth (2020-2025)
4.4 APAC Small Nucleic Acid Drug Market Size Growth (2020-2025)
4.5 Europe Small Nucleic Acid Drug Market Size Growth (2020-2025)
4.6 Middle East & Africa Small Nucleic Acid Drug Market Size Growth (2020-2025)
5 Americas
5.1 Americas Small Nucleic Acid Drug Market Size by Country (2020-2025)
5.2 Americas Small Nucleic Acid Drug Market Size by Type (2020-2025)
5.3 Americas Small Nucleic Acid Drug Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Small Nucleic Acid Drug Market Size by Region (2020-2025)
6.2 APAC Small Nucleic Acid Drug Market Size by Type (2020-2025)
6.3 APAC Small Nucleic Acid Drug Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Small Nucleic Acid Drug Market Size by Country (2020-2025)
7.2 Europe Small Nucleic Acid Drug Market Size by Type (2020-2025)
7.3 Europe Small Nucleic Acid Drug Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Small Nucleic Acid Drug by Region (2020-2025)
8.2 Middle East & Africa Small Nucleic Acid Drug Market Size by Type (2020-2025)
8.3 Middle East & Africa Small Nucleic Acid Drug Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Small Nucleic Acid Drug Market Forecast
10.1 Global Small Nucleic Acid Drug Forecast by Region (2026-2031)
10.1.1 Global Small Nucleic Acid Drug Forecast by Region (2026-2031)
10.1.2 Americas Small Nucleic Acid Drug Forecast
10.1.3 APAC Small Nucleic Acid Drug Forecast
10.1.4 Europe Small Nucleic Acid Drug Forecast
10.1.5 Middle East & Africa Small Nucleic Acid Drug Forecast
10.2 Americas Small Nucleic Acid Drug Forecast by Country (2026-2031)
10.2.1 United States Market Small Nucleic Acid Drug Forecast
10.2.2 Canada Market Small Nucleic Acid Drug Forecast
10.2.3 Mexico Market Small Nucleic Acid Drug Forecast
10.2.4 Brazil Market Small Nucleic Acid Drug Forecast
10.3 APAC Small Nucleic Acid Drug Forecast by Region (2026-2031)
10.3.1 China Small Nucleic Acid Drug Market Forecast
10.3.2 Japan Market Small Nucleic Acid Drug Forecast
10.3.3 Korea Market Small Nucleic Acid Drug Forecast
10.3.4 Southeast Asia Market Small Nucleic Acid Drug Forecast
10.3.5 India Market Small Nucleic Acid Drug Forecast
10.3.6 Australia Market Small Nucleic Acid Drug Forecast
10.4 Europe Small Nucleic Acid Drug Forecast by Country (2026-2031)
10.4.1 Germany Market Small Nucleic Acid Drug Forecast
10.4.2 France Market Small Nucleic Acid Drug Forecast
10.4.3 UK Market Small Nucleic Acid Drug Forecast
10.4.4 Italy Market Small Nucleic Acid Drug Forecast
10.4.5 Russia Market Small Nucleic Acid Drug Forecast
10.5 Middle East & Africa Small Nucleic Acid Drug Forecast by Region (2026-2031)
10.5.1 Egypt Market Small Nucleic Acid Drug Forecast
10.5.2 South Africa Market Small Nucleic Acid Drug Forecast
10.5.3 Israel Market Small Nucleic Acid Drug Forecast
10.5.4 Turkey Market Small Nucleic Acid Drug Forecast
10.6 Global Small Nucleic Acid Drug Forecast by Type (2026-2031)
10.7 Global Small Nucleic Acid Drug Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Small Nucleic Acid Drug Forecast
11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Small Nucleic Acid Drug Product Offered
11.1.3 Sarepta Therapeutics Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Small Nucleic Acid Drug Product Offered
11.2.3 Ionis Pharmaceuticals Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Small Nucleic Acid Drug Product Offered
11.3.3 Alnylam Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Small Nucleic Acid Drug Product Offered
11.4.3 Biogen Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Small Nucleic Acid Drug Product Offered
11.5.3 Nippon Shinyaku Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Small Nucleic Acid Drug Product Offered
11.6.3 Sobi Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Small Nucleic Acid Drug Product Offered
11.7.3 Novartis Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Jazz Pharmaceuticals
11.8.1 Jazz Pharmaceuticals Company Information
11.8.2 Jazz Pharmaceuticals Small Nucleic Acid Drug Product Offered
11.8.3 Jazz Pharmaceuticals Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Jazz Pharmaceuticals Main Business Overview
11.8.5 Jazz Pharmaceuticals Latest Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Small Nucleic Acid Drug Product Offered
11.9.3 AstraZeneca Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 AstraZeneca Main Business Overview
11.9.5 AstraZeneca Latest Developments
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Information
11.10.2 Novo Nordisk Small Nucleic Acid Drug Product Offered
11.10.3 Novo Nordisk Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Novo Nordisk Main Business Overview
11.10.5 Novo Nordisk Latest Developments
11.11 Astellas Pharma
11.11.1 Astellas Pharma Company Information
11.11.2 Astellas Pharma Small Nucleic Acid Drug Product Offered
11.11.3 Astellas Pharma Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Astellas Pharma Main Business Overview
11.11.5 Astellas Pharma Latest Developments
11.12 Geron Corporation
11.12.1 Geron Corporation Company Information
11.12.2 Geron Corporation Small Nucleic Acid Drug Product Offered
11.12.3 Geron Corporation Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Geron Corporation Main Business Overview
11.12.5 Geron Corporation Latest Developments
11.13 CureVac
11.13.1 CureVac Company Information
11.13.2 CureVac Small Nucleic Acid Drug Product Offered
11.13.3 CureVac Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 CureVac Main Business Overview
11.13.5 CureVac Latest Developments
11.14 Regulus Therapeutics
11.14.1 Regulus Therapeutics Company Information
11.14.2 Regulus Therapeutics Small Nucleic Acid Drug Product Offered
11.14.3 Regulus Therapeutics Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Regulus Therapeutics Main Business Overview
11.14.5 Regulus Therapeutics Latest Developments
11.15 ProQR
11.15.1 ProQR Company Information
11.15.2 ProQR Small Nucleic Acid Drug Product Offered
11.15.3 ProQR Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 ProQR Main Business Overview
11.15.5 ProQR Latest Developments
11.16 Secarna
11.16.1 Secarna Company Information
11.16.2 Secarna Small Nucleic Acid Drug Product Offered
11.16.3 Secarna Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Secarna Main Business Overview
11.16.5 Secarna Latest Developments
11.17 MiNA Therapeutics
11.17.1 MiNA Therapeutics Company Information
11.17.2 MiNA Therapeutics Small Nucleic Acid Drug Product Offered
11.17.3 MiNA Therapeutics Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 MiNA Therapeutics Main Business Overview
11.17.5 MiNA Therapeutics Latest Developments
11.18 Sylentis
11.18.1 Sylentis Company Information
11.18.2 Sylentis Small Nucleic Acid Drug Product Offered
11.18.3 Sylentis Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Sylentis Main Business Overview
11.18.5 Sylentis Latest Developments
11.19 Arrowhead
11.19.1 Arrowhead Company Information
11.19.2 Arrowhead Small Nucleic Acid Drug Product Offered
11.19.3 Arrowhead Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Arrowhead Main Business Overview
11.19.5 Arrowhead Latest Developments
11.20 Silence Therapeutics
11.20.1 Silence Therapeutics Company Information
11.20.2 Silence Therapeutics Small Nucleic Acid Drug Product Offered
11.20.3 Silence Therapeutics Small Nucleic Acid Drug Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Silence Therapeutics Main Business Overview
11.20.5 Silence Therapeutics Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
